- In January 2025, Roche announced the initiation of Phase III clinical trials for its novel monoclonal antibody RGX-202, targeting HER2-positive gastric cancer. This highlights Roche’s continued leadership in oncology biologics by expanding its pipeline to address unmet needs in gastric cancer treatment
- In February 2025, AbbVie received FDA approval for Skyrizi (risankizumab) for the treatment of moderate to severe Crohn’s disease. Skyrizi, a humanized monoclonal antibody, previously approved for psoriasis, represents AbbVie’s growing dominance in the autoimmune therapeutic segment
- In March 2025, the European Medicines Agency (EMA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) by Johnson & Johnson for newly diagnosed multiple myeloma. This subcutaneous version offers increased convenience and reduced infusion time for patients
- In April 2025, Merck announced positive Phase III results from the KEYNOTE-522 trial for Keytruda (pembrolizumab) in early-stage triple-negative breast cancer, demonstrating improved response rates when combined with chemotherapy
- In May 2025, the European Commission approved Tezepelumab, developed by Amgen, for severe asthma. This monoclonal antibody targets thymic stromal lymphopoietin (TSLP), offering a new treatment option for patients unresponsive to standard therapies
